Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Solasia Pharma KK ( (JP:4597) ) just unveiled an announcement.
Solasia Pharma K.K. has reported its consolidated financial results for the fiscal year ending December 31, 2024, along with updates on its major pipeline products. Sancuso® faced a significant decline in sales in China due to shipment constraints after transferring its manufacturing facility. On the other hand, DARVIAS® Injection received marketing approval in Japan, with Nippon Kayaku handling its sales, and efforts are underway to seek regulatory approval in South America, where HB Human BioScience is involved.
More about Solasia Pharma KK
Solasia Pharma K.K. operates in the pharmaceutical industry, focusing on the development and commercialization of oncology and supportive care products. Its primary products include Sancuso®, a transdermal delivery system for chemotherapy-induced nausea and vomiting, and DARVIAS® Injection, an organic arsenic compound for the treatment of peripheral T-cell lymphoma. The company has a market focus in regions including China and Japan, and it collaborates with partners like Lee’s Pharmaceutical and Nippon Kayaku for product sales and distribution.
YTD Price Performance: 21.05%
Average Trading Volume: 304
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €53.48M
See more data about 4597 stock on TipRanks’ Stock Analysis page.